Form 10-Q Apellis Pharmaceuticals, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
JPMorgan Take-Aways on Apellis Pharmaceuticals (APLS) Earnings
May 7, 2024 7:59 AM EDTJPMorgan analyst Anupam Rama reiterated an Overweight rating and $79.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "The quarter was highlighted by a 1Q24 beat for Syfovre, though we suspect the call will largely focus on near-term GA market dynamics post... More



